Trade Names:ActHIB- Powder for Injection, lyophilized 10 mcg purified capsular polysaccharide, 24 mcg tetanus toxoid/0.5 mL
Trade Names:Comvax- Injection 7.5 mcg Haemophilus b PRP purified capsular polysaccharide, 125 mcg Neisseria meningitidis OMPC, 5 mcg hepatitis B surface antigen, about 225 mcg aluminum, and 35 mcg sodium borate/0.5 mL
Trade Names:PedvaxHIB, Liquid- Injection 7.5 mcg Haemophilus b PRP, 125 mcg Neisseria meningitidis OMPC, and 225 mcg aluminum/0.5 mL
Induces specific protective antibodies against Haemophilus influenzae type b (Hib).
Induction of active immunity against Hib infection. Routine immunization of all infants beginning at age 2 mo is recommended.
Hypersensitivity to any product component (some products contain thimerosal).
IM Beginning at 2 mo of age, give 3 doses, 2 mo apart, plus a booster dose at 15 to 18 mo.PedvaxHIBPediatric
IM Beginning at 2 mo of age, give 2 doses, 2 mo apart, plus a booster dose at 12 mo.
Store vials in refrigerator (36° to 46°F). Do not freeze.
None well documented.
Diagnostic value of antigen detection (eg, with latex agglutination kits) may be diminished in suspected Hib disease within few days to 2 wk after immunization.
Irritability; fever; restless sleep; convulsions.
Diarrhea; vomiting; loss of appetite.
Guillain-Barré syndrome; local erythema; swelling; tenderness; induration.
Category C .
PedvaxHIB is not recommended in children younger than 6 wk of age.
Administer Hib vaccine with caution to patients receiving anticoagulant therapy.
In general, complete vaccination series begun with one brand of Hib vaccine with that brand unless specific information about interchangeability is available.
Stopper for diluent vial for ActHIB contains dry natural latex rubber.
Copyright © 2009 Wolters Kluwer Health.